Genticel Appoints Dr Gerald Moeller as Vice-President of Its Supervisory Board

Toulouse, France, November 7, 2013 - Genticel, a biopharmaceutical company that develops innovative vaccines for patients infected with the human papillomavirus (HPV), has appointed a new vice-president to the supervisory board. 

Dr Gerald Moeller, PhD has over 35 years experience in the pharmaceutical and diagnostics industry. He has been an investment adviser at HBM Partners in Switzerland since 2002 and chairs the supervisory boards of a number of health sector companies, including 4Sigma Ltd, Definiens AG, Invendo-Medical GmbH and MorphoSys AG. He is also a board member with FIND Foundation and Illumina Inc. 

"We are very pleased that Dr Moeller is joining our supervisory board," says Benedikt Timmerman, founder and CEO of Genticel. "His wealth of expertise in the pharmaceutical industry represents a considerable asset for Genticel, especially at a key moment in our development. We are launching the phase II clinical trial of our lead product, ProCervix, in Europe - so it is a priority for Genticel to forge close ties with major pharmaceutical industry players. Gerry's experience in this industry and his strategic advice will be invaluable in this." 

"The results of the phase I trial of ProCervix are very encouraging. It is the first vaccine to meet the medical needs of over 90 million women infected with HPV16 and/or 18," says Dr Gerald Moeller. "I am delighted to help Genticel reap the benefits of such promising projects." 

The supervisory board at Genticel is chaired by Professor Thierry Hercend. The membership comprises Ludovic de Meeus d'Argenteuil, co-founder of Genticel; Alain Munoz, representing Kurma Life Sciences; Raphael Wisniewski, director of investment at Edmond de Rothschild Investment Partners (EdRIP); Olivier Martinez, director of investment, life sciences, BPI France; Alexandre Flageul, partner at Amundi Private Equity Funds; and Dr Didier Hoch, an independent industry member. 

About Dr Gerald Moeller

In the pharmaceutical industry, Dr Moeller was chief executive officer of the Boehringer Mannheim Group and director of international development and strategic marketing for the pharmaceutical division. He was also a member of Roche's executive committee. 

In the biotechnology sector, Dr Moeller is a member of the board of companies such as Bionostics Inc., BRAHMS AG, MTM Laboratories AG, PowderJect Pharmaceuticals PLC, Strakan Ltd, Vivacta Ltd and Sugen Inc. All these companies were successfully acquired by leading companies in their specific sectors of the industry. 

About Genticel S.A. 

GENTICEL is a clinical stage biopharmaceutical company based in Paris and Toulouse, France, which develops vaccines for patients infected with Human Papillomavirus (HPV). Besides ProCervix, its other pipeline products include CyaA-based multivalent HPV vaccines with additional virus subtype coverage. For more information, please visit http://www.genticel.com 

To download a photo of Dr Moeller click here: http://www.ala.com/article.php?id=299 

Mark Tidmarsh

[email protected]

ANDREW LLOYD & ASSOCIATES

http://www.ala.com

https://twitter.com/ALA_Group 

Tel UK: +44 1273 675100

Tel France: +33 1 56 54 07 00 

Tel US: +1 617 517 0146 

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION 

Suggested Articles

Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.

In this week's EuroBiotech Report, Healx raises $56 million, Boehringer's VC wing backs anti-cancer virus startup and Ipsen bags Blueprint drug.

In our EuroBiotech roundup this week, GammaDelta forms antibody spinout, gene therapy startup raises cash and Amsterdam plans medical business park.